1. Home
  2. URGN vs HLIT Comparison

URGN vs HLIT Comparison

Compare URGN & HLIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • URGN
  • HLIT
  • Stock Information
  • Founded
  • URGN 2004
  • HLIT 1988
  • Country
  • URGN United States
  • HLIT United States
  • Employees
  • URGN N/A
  • HLIT N/A
  • Industry
  • URGN Biotechnology: Pharmaceutical Preparations
  • HLIT Radio And Television Broadcasting And Communications Equipment
  • Sector
  • URGN Health Care
  • HLIT Technology
  • Exchange
  • URGN Nasdaq
  • HLIT Nasdaq
  • Market Cap
  • URGN 896.3M
  • HLIT 1.0B
  • IPO Year
  • URGN 2017
  • HLIT 1995
  • Fundamental
  • Price
  • URGN $19.44
  • HLIT $9.19
  • Analyst Decision
  • URGN Strong Buy
  • HLIT Buy
  • Analyst Count
  • URGN 8
  • HLIT 6
  • Target Price
  • URGN $28.50
  • HLIT $11.50
  • AVG Volume (30 Days)
  • URGN 1.0M
  • HLIT 1.2M
  • Earning Date
  • URGN 08-07-2025
  • HLIT 07-28-2025
  • Dividend Yield
  • URGN N/A
  • HLIT N/A
  • EPS Growth
  • URGN N/A
  • HLIT 16.91
  • EPS
  • URGN N/A
  • HLIT 0.58
  • Revenue
  • URGN $94,238,000.00
  • HLIT $689,084,000.00
  • Revenue This Year
  • URGN $39.80
  • HLIT N/A
  • Revenue Next Year
  • URGN $108.94
  • HLIT $21.74
  • P/E Ratio
  • URGN N/A
  • HLIT $15.81
  • Revenue Growth
  • URGN 10.85
  • HLIT 24.14
  • 52 Week Low
  • URGN $3.42
  • HLIT $7.80
  • 52 Week High
  • URGN $21.02
  • HLIT $15.46
  • Technical
  • Relative Strength Index (RSI)
  • URGN 58.49
  • HLIT 54.58
  • Support Level
  • URGN $18.65
  • HLIT $8.67
  • Resistance Level
  • URGN $20.11
  • HLIT $9.16
  • Average True Range (ATR)
  • URGN 1.20
  • HLIT 0.27
  • MACD
  • URGN -0.24
  • HLIT 0.03
  • Stochastic Oscillator
  • URGN 60.08
  • HLIT 82.14

About URGN UroGen Pharma Ltd.

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.

About HLIT Harmonic Inc.

Harmonic Inc engaged in broadband access solutions that enable broadband operators to more efficiently and effectively deploy high-speed internet for data, voice, and video services for their customers and versatile and high-performance video delivery software, products, system solutions and services that enable its customers to efficiently create, prepare, store, playout and deliver a full range of high-quality broadcast and streaming video services to consumer devices, including televisions, personal computers, laptops, tablets, and smartphones. It has two segments, Broadband which provides broadband access solutions and related services, and Others; and Video business provides video processing and production and playout solutions and services, and Others.

Share on Social Networks: